Roquefort Therapeutics PLC (LSE:ROQ) has signed an out-licensing agreement with Pleiades Pharma Ltd for its MK Cell intellectual property, a deal that could generate up to $25 million in milestone payments in addition to ongoing royalties on future sales. The transaction forms part of a wider corporate restructuring strategy designed to streamline operations and unlock shareholder value.
As part of this restructuring, Roquefort also plans to sell its subsidiary, Lyramid Pty Ltd, to Pleiades Pharma, pending the latter’s successful completion of a fundraising round. These steps are intended to strengthen the company’s balance sheet and enable a sharper focus on strategic growth opportunities, including a transformative acquisition involving A2A Pharmaceuticals and Coiled Therapeutics. The company expects the reorganization to reinforce its position as a focused, innovation-driven biotech player.
More about Roquefort Therapeutics PLC
Roquefort Therapeutics PLC is a biotechnology company listed on the Main Market of the London Stock Exchange. The firm specializes in developing novel cancer therapies and holds exclusive rights to AO-252, a first-in-class drug candidate targeting the TACC3 protein. Roquefort is also advancing research programs in MK Cell and STAT-6, aimed at expanding its oncology-focused drug development pipeline.
Leave a Reply